Identification
NameParicalcitol
Accession NumberDB00910  (APRD01165)
TypeSmall Molecule
GroupsApproved, Investigational
Description

Paricalcitol is a synthetic vitamin D analog. Paricalcitol has been used to reduce parathyroid hormone levels. Paricalcitol is indicated for the prevention and treatment of secondary hyperparathyroidism associated with chronic renal failure.

Structure
Thumb
Synonyms
19-Nor-1alpha,25-dihydroxyvitamin D2
Paricalcitol
Zemplar
External IDs COMPOUND 49510
Product Ingredients Not Available
Product Images
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
ParicalcitolCapsule, liquid filled1 ug/1OralZydus Pharmaceuticals Usa, Inc.2010-06-14Not applicableUs
ParicalcitolInjection, solution2 ug/mLIntravenousAccord Healthcare Limited2016-03-01Not applicableUs
ParicalcitolInjection, solution5 ug/mLIntravenousHospira, Inc.2014-11-01Not applicableUs
ParicalcitolInjection5 ug/mLIntravenousWest Ward Pharmaceutical2014-11-18Not applicableUs
ParicalcitolCapsule, liquid filled2 ug/1OralZydus Pharmaceuticals Usa, Inc.2010-06-14Not applicableUs
ParicalcitolInjection, solution5 ug/mLIntravenousAccord Healthcare Limited2016-03-01Not applicableUs
ParicalcitolInjection2 ug/mLIntravenousWest Ward Pharmaceutical2014-11-18Not applicableUs
ParicalcitolInjection, solution2 ug/mLIntravenousHospira, Inc.2014-11-01Not applicableUs
ParicalcitolInjection5 ug/mLIntravenousWest Ward Pharmaceutical2014-11-18Not applicableUs
ZemplarInjection, solution5 ug/mLIntravenousAbbvie1998-04-17Not applicableUs
ZemplarCapsule, liquid filled1 ug/1OralAbbvie2010-06-14Not applicableUs
ZemplarCapsule, liquid filled4 ug/1OralAbbvie2010-06-142015-12-29Us
ZemplarInjection, solution2 ug/mLIntravenousAbbvie1998-04-17Not applicableUs
ZemplarSolution5 mcgIntravenousAbbvie2005-12-012012-11-03Canada
ZemplarCapsule, liquid filled2 ug/1OralAbbvie2010-06-14Not applicableUs
ZemplarCapsule, liquid filled1 ug/1OralCardinal Health2005-05-26Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
ParicalcitolCapsule, gelatin coated4 ug/1OralRising Pharmaceuticals2015-11-03Not applicableUs
ParicalcitolCapsule, liquid filled1 ug/1OralBanner Pharmacaps2014-03-27Not applicableUs
ParicalcitolInjection5 ug/mLIntravenousAmneal Biosciences2017-03-09Not applicableUs
ParicalcitolCapsule, liquid filled2 ug/1OralAurobindo Pharma2016-01-14Not applicableUs
ParicalcitolInjection, solution5 ug/mLIntravenousDr Reddy's Laboratories2016-09-06Not applicableUs
ParicalcitolCapsule2 ug/1OralAlvogen, Inc.2016-03-012016-03-11Us
ParicalcitolCapsule, liquid filled4 ug/1OralGolden State Medical Supply2014-03-27Not applicableUs
ParicalcitolCapsule1 ug/1OralAmneal Pharmaceuticals2016-01-15Not applicableUs
ParicalcitolCapsule1 ug/1OralGolden State Medical Supply2016-08-29Not applicableUs
ParicalcitolInjection, solution2 ug/mLIntravenousDr Reddy's Laboratories2016-09-06Not applicableUs
ParicalcitolCapsule, gelatin coated2 ug/1OralRising Pharmaceuticals2015-11-03Not applicableUs
ParicalcitolInjection2 ug/mLIntravenousAmneal Biosciences2017-03-09Not applicableUs
ParicalcitolCapsule, liquid filled1 ug/1OralAurobindo Pharma2016-01-14Not applicableUs
ParicalcitolCapsule4 mg/1OralBanner Life Sciences Llc.2015-10-01Not applicableUs
ParicalcitolCapsule, liquid filled1 ug/1OralDr Reddy's Laboratories2014-06-25Not applicableUs
ParicalcitolCapsule, liquid filled2 ug/1OralTime Cap Laboratories2015-12-30Not applicableUs
ParicalcitolCapsule2 ug/1OralBionpharma Inc.2016-08-16Not applicableUs
ParicalcitolCapsule, liquid filled4 ug/1OralGolden State Medical Supply2015-12-07Not applicableUs
ParicalcitolCapsule, liquid filled1 ug/1OralGolden State Medical Supply2014-04-23Not applicableUs
ParicalcitolCapsule, liquid filled2 ug/1OralTeva2013-09-302017-03-31Us00093 7657 56 nlmimage10 5e382f71
ParicalcitolCapsule, liquid filled2 ug/1OralMARKSANS PHARMA LIMITED2016-10-18Not applicableUs
ParicalcitolCapsule1 mg/1OralBanner Life Sciences Llc.2015-09-02Not applicableUs
ParicalcitolCapsule, liquid filled2 ug/1OralBanner Pharmacaps2014-03-27Not applicableUs
ParicalcitolInjection10 ug/2mLIntravenousAmneal Biosciences2017-03-09Not applicableUs
ParicalcitolCapsule, liquid filled4 ug/1OralAurobindo Pharma2016-01-14Not applicableUs
ParicalcitolInjection, solution5 ug/mLIntravenousDr Reddy's Laboratories2016-09-06Not applicableUs
ParicalcitolCapsule4 ug/1OralAlvogen, Inc.2016-03-012016-03-11Us
ParicalcitolCapsule, liquid filled1 ug/1OralAmerincan Health Packaging2015-03-312017-04-14Us00093 7656 56 nlmimage10 5e382f41
ParicalcitolCapsule2 ug/1OralAmneal Pharmaceuticals2016-01-15Not applicableUs
ParicalcitolCapsule2 ug/1OralGolden State Medical Supply2016-08-29Not applicableUs
ParicalcitolCapsule, liquid filled4 ug/1OralTime Cap Laboratories2017-01-03Not applicableUs
ParicalcitolCapsule4 ug/1OralBionpharma Inc.2016-08-16Not applicableUs
ParicalcitolCapsule, liquid filled1 ug/1OralGolden State Medical Supply2015-12-07Not applicableUs
ParicalcitolCapsule, liquid filled2 ug/1OralDr Reddy's Laboratories2014-06-25Not applicableUs
ParicalcitolCapsule1 ug/1OralAlvogen, Inc.2016-03-012016-03-11Us
ParicalcitolCapsule, liquid filled2 ug/1OralGolden State Medical Supply2014-04-23Not applicableUs
ParicalcitolCapsule, liquid filled4 ug/1OralTeva2013-09-302017-05-31Us00093 7658 56 nlmimage10 63383181
ParicalcitolCapsule, liquid filled4 ug/1OralMARKSANS PHARMA LIMITED2016-10-18Not applicableUs
ParicalcitolCapsule, gelatin coated1 ug/1OralRising Pharmaceuticals2015-11-03Not applicableUs
ParicalcitolCapsule4 ug/1OralAmneal Pharmaceuticals2016-01-15Not applicableUs
ParicalcitolCapsule4 ug/1OralGolden State Medical Supply2016-08-29Not applicableUs
ParicalcitolCapsule2 mg/1OralBanner Life Sciences Llc.2015-10-01Not applicableUs
ParicalcitolCapsule, liquid filled4 ug/1OralBanner Pharmacaps2014-03-27Not applicableUs
ParicalcitolInjection10 ug/2mLIntravenousAmneal Biosciences2017-03-09Not applicableUs
ParicalcitolCapsule, liquid filled1 ug/1OralTime Cap Laboratories2017-01-03Not applicableUs
ParicalcitolCapsule1 ug/1OralBionpharma Inc.2016-08-16Not applicableUs
ParicalcitolInjection, solution5 ug/mLIntravenousDr Reddy's Laboratories2016-09-06Not applicableUs
ParicalcitolCapsule, liquid filled2 ug/1OralGolden State Medical Supply2015-12-07Not applicableUs
ParicalcitolCapsule, liquid filled4 ug/1OralDr Reddy's Laboratories2014-06-25Not applicableUs
ParicalcitolCapsule, liquid filled1 ug/1OralTeva2013-09-302017-04-30Us
ParicalcitolCapsule, liquid filled1 ug/1OralMARKSANS PHARMA LIMITED2016-10-12Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
Categories
UNII6702D36OG5
CAS number131918-61-1
WeightAverage: 416.6365
Monoisotopic: 416.329045274
Chemical FormulaC27H44O3
InChI KeyBPKAHTKRCLCHEA-UBFJEZKGSA-N
InChI
InChI=1S/C27H44O3/c1-18(8-9-19(2)26(3,4)30)24-12-13-25-21(7-6-14-27(24,25)5)11-10-20-15-22(28)17-23(29)16-20/h8-11,18-19,22-25,28-30H,6-7,12-17H2,1-5H3/b9-8+,21-11+/t18-,19+,22-,23-,24-,25+,27-/m1/s1
IUPAC Name
(1R,3R)-5-{2-[(1R,3aS,4E,7aR)-1-[(2R,3E,5S)-6-hydroxy-5,6-dimethylhept-3-en-2-yl]-7a-methyl-octahydro-1H-inden-4-ylidene]ethylidene}cyclohexane-1,3-diol
SMILES
[H]C1CC[C@]2(C)[C@]([H])(CC[C@@]2([H])\C1=C\C=C1C[C@@H](O)C[[email protected]](O)C1)[[email protected]](C)\C=C\[[email protected]](C)C(O)(C)C
Pharmacology
Indication

For treatment of secondary hyperparathyroidism associated with chronic kidney disease (CKD) Stage 3 and 4

Structured Indications
Pharmacodynamics

Secondary hyperparathyroidism is characterized by an elevation in parathyroid hormone (PTH) associated with inadequate levels of active vitamin D hormone. The source of vitamin D in the body is from synthesis in the skin and from dietary intake. Vitamin D requires two sequential hydroxylations in the liver and the kidney to bind to and to activate the vitamin D receptor (VDR). The endogenous VDR activator, calcitriol [1,25(OH)2 D3], is a hormone that binds to VDRs that are present in the parathyroid gland, intestine, kidney, and bone to maintain parathyroid function and calcium and phosphorus homeostasis, and to VDRs found in many other tissues, including prostate, endothelium and immune cells. VDR activation is essential for the proper formation and maintenance of normal bone. In the diseased kidney, the activation of vitamin D is diminished, resulting in a rise of PTH, subsequently leading to secondary hyperparathyroidism and disturbances in the calcium and phosphorus homeostasis.1 Decreased levels of 1,25(OH)2 D3 have been observed in early stages of chronic kidney disease. The decreased levels of 1,25(OH)2 D3 and resultant elevated PTH levels, both of which often precede abnormalities in serum calcium and phosphorus, affect bone turnover rate and may result in renal osteodystrophy. An in vitro study indicates that paricalcitol is not an inhibitor of CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1 or CYP3A at concentrations up to 50 nM (21 ng/mL).

Mechanism of action

Paricalcitol is a synthetic, biologically active vitamin D analog of calcitriol with modifications to the side chain (D2) and the A (19-nor) ring. Preclinical andin vitro studies have demonstrated that paricalcitol's biological actions are mediated through binding of the VDR, which results in the selective activation of vitamin D responsive pathways. Vitamin D and paricalcitol have been shown to reduce parathyroid hormone levels by inhibiting PTH synthesis and secretion.

TargetKindPharmacological actionActionsOrganismUniProt ID
Vitamin D3 receptorProteinyes
agonist
HumanP11473 details
Related Articles
Absorption

Well absorbed

Volume of distribution
  • 30.8 ± 7.5 L [CKD Stage 5-HD]
  • 34.9 ± 9.5 L [CKD Stage 5-PD]
  • 23.8 L [healthy subjects]
Protein binding

99.8% (bound to plasma proteins)

Metabolism

Metabolized by multiple hepatic and non-hepatic enzymes, including mitochondrial CYP24, as well as CYP3A4 and UGT1A4

Route of elimination

Paricalcitol is excreted primarily by hepatobiliary excretion.

Half life

4 to 6 hours

Clearance
  • 1.49 +/- 0.60 L/h [chronic kidney disease Stage 5 with hemodialysis]
  • 1.54 +/- 0.95 L/h [chronic kidney disease Stage 5with peritoneal dialysis]
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Interactions
Drug Interactions
DrugInteractionDrug group
AcetyldigitoxinParicalcitol may increase the arrhythmogenic activities of Acetyldigitoxin.Approved
AlfacalcidolThe risk or severity of adverse effects can be increased when Alfacalcidol is combined with Paricalcitol.Approved, Nutraceutical
Aluminum hydroxideThe serum concentration of Aluminum hydroxide can be increased when it is combined with Paricalcitol.Approved
AmiodaroneThe serum concentration of Paricalcitol can be increased when it is combined with Amiodarone.Approved, Investigational
AprepitantThe serum concentration of Paricalcitol can be increased when it is combined with Aprepitant.Approved, Investigational
AtazanavirThe serum concentration of Paricalcitol can be increased when it is combined with Atazanavir.Approved, Investigational
AtomoxetineThe metabolism of Paricalcitol can be decreased when combined with Atomoxetine.Approved
BendroflumethiazideBendroflumethiazide may increase the hypercalcemic activities of Paricalcitol.Approved
BexaroteneThe serum concentration of Paricalcitol can be decreased when it is combined with Bexarotene.Approved, Investigational
BoceprevirThe serum concentration of Paricalcitol can be increased when it is combined with Boceprevir.Withdrawn
BortezomibThe metabolism of Paricalcitol can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Paricalcitol can be decreased when it is combined with Bosentan.Approved, Investigational
CalcidiolThe risk or severity of adverse effects can be increased when Calcidiol is combined with Paricalcitol.Approved, Nutraceutical
CalcipotriolThe risk or severity of adverse effects can be increased when Calcipotriol is combined with Paricalcitol.Approved
CalcitriolThe risk or severity of adverse effects can be increased when Calcitriol is combined with Paricalcitol.Approved, Nutraceutical
CalciumThe risk or severity of adverse effects can be increased when Calcium is combined with Paricalcitol.Nutraceutical
Calcium AcetateThe risk or severity of adverse effects can be increased when Calcium Acetate is combined with Paricalcitol.Approved
Calcium CarbonateThe risk or severity of adverse effects can be increased when Calcium carbonate is combined with Paricalcitol.Approved
Calcium ChlorideThe risk or severity of adverse effects can be increased when Calcium Chloride is combined with Paricalcitol.Approved
Calcium CitrateThe risk or severity of adverse effects can be increased when Calcium citrate is combined with Paricalcitol.Approved
Calcium glubionateThe risk or severity of adverse effects can be increased when Calcium glubionate is combined with Paricalcitol.Approved
Calcium GluceptateThe risk or severity of adverse effects can be increased when Calcium Gluceptate is combined with Paricalcitol.Approved
Calcium gluconateThe risk or severity of adverse effects can be increased when Calcium gluconate is combined with Paricalcitol.Approved, Vet Approved
CarbamazepineThe metabolism of Paricalcitol can be increased when combined with Carbamazepine.Approved, Investigational
CeritinibThe serum concentration of Paricalcitol can be increased when it is combined with Ceritinib.Approved
ChlorothiazideChlorothiazide may increase the hypercalcemic activities of Paricalcitol.Approved, Vet Approved
ChlorthalidoneChlorthalidone may increase the hypercalcemic activities of Paricalcitol.Approved
CholecalciferolThe risk or severity of adverse effects can be increased when Cholecalciferol is combined with Paricalcitol.Approved, Nutraceutical
CholestyramineThe serum concentration of Paricalcitol can be decreased when it is combined with Cholestyramine.Approved
ClarithromycinThe serum concentration of Paricalcitol can be increased when it is combined with Clarithromycin.Approved
ClemastineThe metabolism of Paricalcitol can be decreased when combined with Clemastine.Approved
ClotrimazoleThe metabolism of Paricalcitol can be decreased when combined with Clotrimazole.Approved, Vet Approved
CobicistatThe serum concentration of Paricalcitol can be increased when it is combined with Cobicistat.Approved
ColesevelamThe serum concentration of Paricalcitol can be decreased when it is combined with Colesevelam.Approved
ColestipolThe serum concentration of Paricalcitol can be decreased when it is combined with Colestipol.Approved
ConivaptanThe serum concentration of Paricalcitol can be increased when it is combined with Conivaptan.Approved, Investigational
CrizotinibThe metabolism of Paricalcitol can be decreased when combined with Crizotinib.Approved
CyclosporineThe metabolism of Paricalcitol can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
DabrafenibThe serum concentration of Paricalcitol can be decreased when it is combined with Dabrafenib.Approved
DanazolDanazol may increase the hypercalcemic activities of Paricalcitol.Approved
DarunavirThe serum concentration of Paricalcitol can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Paricalcitol can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Paricalcitol can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Paricalcitol can be decreased when combined with Delavirdine.Approved
DeslanosideParicalcitol may increase the arrhythmogenic activities of Deslanoside.Approved
DexamethasoneThe serum concentration of Paricalcitol can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DigitoxinParicalcitol may increase the arrhythmogenic activities of Digitoxin.Approved
DigoxinThe risk or severity of adverse effects can be increased when Paricalcitol is combined with Digoxin.Approved
DihydroergotamineThe metabolism of Paricalcitol can be decreased when combined with Dihydroergotamine.Approved
DihydrotachysterolThe risk or severity of adverse effects can be increased when Dihydrotachysterol is combined with Paricalcitol.Approved
DiltiazemThe metabolism of Paricalcitol can be decreased when combined with Diltiazem.Approved
DoxercalciferolThe risk or severity of adverse effects can be increased when Doxercalciferol is combined with Paricalcitol.Approved
DoxycyclineThe metabolism of Paricalcitol can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe metabolism of Paricalcitol can be decreased when combined with Dronedarone.Approved
EfavirenzThe serum concentration of Paricalcitol can be decreased when it is combined with Efavirenz.Approved, Investigational
EnzalutamideThe serum concentration of Paricalcitol can be decreased when it is combined with Enzalutamide.Approved
ErgocalciferolThe risk or severity of adverse effects can be increased when Ergocalciferol is combined with Paricalcitol.Approved, Nutraceutical
ErythromycinThe metabolism of Paricalcitol can be decreased when combined with Erythromycin.Approved, Vet Approved
Eslicarbazepine acetateThe serum concentration of Paricalcitol can be decreased when it is combined with Eslicarbazepine acetate.Approved
EtravirineThe serum concentration of Paricalcitol can be decreased when it is combined with Etravirine.Approved
FluconazoleThe metabolism of Paricalcitol can be decreased when combined with Fluconazole.Approved
FluvoxamineThe metabolism of Paricalcitol can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Paricalcitol can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Paricalcitol can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Paricalcitol can be increased when combined with Fosphenytoin.Approved
Fusidic AcidThe serum concentration of Paricalcitol can be increased when it is combined with Fusidic Acid.Approved
HydrochlorothiazideHydrochlorothiazide may increase the hypercalcemic activities of Paricalcitol.Approved, Vet Approved
HydroflumethiazideHydroflumethiazide may increase the hypercalcemic activities of Paricalcitol.Approved
IdelalisibThe serum concentration of Paricalcitol can be increased when it is combined with Idelalisib.Approved
ImatinibThe metabolism of Paricalcitol can be decreased when combined with Imatinib.Approved
IndapamideIndapamide may increase the hypercalcemic activities of Paricalcitol.Approved
IndinavirThe serum concentration of Paricalcitol can be increased when it is combined with Indinavir.Approved
IsavuconazoniumThe metabolism of Paricalcitol can be decreased when combined with Isavuconazonium.Approved, Investigational
IsradipineThe metabolism of Paricalcitol can be decreased when combined with Isradipine.Approved
ItraconazoleThe serum concentration of Paricalcitol can be increased when it is combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Paricalcitol can be increased when it is combined with Ivacaftor.Approved
KetoconazoleThe serum concentration of Paricalcitol can be increased when it is combined with Ketoconazole.Approved, Investigational
LopinavirThe serum concentration of Paricalcitol can be increased when it is combined with Lopinavir.Approved
LovastatinThe metabolism of Paricalcitol can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Paricalcitol can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Paricalcitol can be increased when combined with Lumacaftor.Approved
MethyclothiazideMethyclothiazide may increase the hypercalcemic activities of Paricalcitol.Approved
MetolazoneMetolazone may increase the hypercalcemic activities of Paricalcitol.Approved
MifepristoneThe serum concentration of Paricalcitol can be increased when it is combined with Mifepristone.Approved, Investigational
MitotaneThe serum concentration of Paricalcitol can be decreased when it is combined with Mitotane.Approved
ModafinilThe serum concentration of Paricalcitol can be decreased when it is combined with Modafinil.Approved, Investigational
NafcillinThe serum concentration of Paricalcitol can be decreased when it is combined with Nafcillin.Approved
NefazodoneThe serum concentration of Paricalcitol can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Paricalcitol can be increased when it is combined with Nelfinavir.Approved
NetupitantThe serum concentration of Paricalcitol can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Paricalcitol can be increased when combined with Nevirapine.Approved
NilotinibThe metabolism of Paricalcitol can be decreased when combined with Nilotinib.Approved, Investigational
OlaparibThe metabolism of Paricalcitol can be decreased when combined with Olaparib.Approved
OleandrinParicalcitol may increase the arrhythmogenic activities of Anvirzel.Experimental
OrlistatThe serum concentration of Paricalcitol can be decreased when it is combined with Orlistat.Approved, Investigational
OsimertinibThe serum concentration of Paricalcitol can be increased when it is combined with Osimertinib.Approved
OuabainParicalcitol may increase the arrhythmogenic activities of Ouabain.Approved
PalbociclibThe serum concentration of Paricalcitol can be increased when it is combined with Palbociclib.Approved
PentobarbitalThe metabolism of Paricalcitol can be increased when combined with Pentobarbital.Approved, Vet Approved
PhenobarbitalThe metabolism of Paricalcitol can be increased when combined with Phenobarbital.Approved
PhenytoinThe metabolism of Paricalcitol can be increased when combined with Phenytoin.Approved, Vet Approved
PolythiazidePolythiazide may increase the hypercalcemic activities of Paricalcitol.Approved
PosaconazoleThe serum concentration of Paricalcitol can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PrimidoneThe metabolism of Paricalcitol can be increased when combined with Primidone.Approved, Vet Approved
QuinethazoneQuinethazone may increase the hypercalcemic activities of Paricalcitol.Approved
RanolazineThe metabolism of Paricalcitol can be decreased when combined with Ranolazine.Approved, Investigational
RifabutinThe metabolism of Paricalcitol can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Paricalcitol can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Paricalcitol can be increased when combined with Rifapentine.Approved
RitonavirThe serum concentration of Paricalcitol can be increased when it is combined with Ritonavir.Approved, Investigational
SaquinavirThe serum concentration of Paricalcitol can be increased when it is combined with Saquinavir.Approved, Investigational
SildenafilThe metabolism of Paricalcitol can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Paricalcitol can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Paricalcitol can be increased when it is combined with Simeprevir.Approved
St. John's WortThe serum concentration of Paricalcitol can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Paricalcitol can be increased when it is combined with Stiripentol.Approved
SucralfateThe serum concentration of Sucralfate can be increased when it is combined with Paricalcitol.Approved
SulfisoxazoleThe metabolism of Paricalcitol can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
TelaprevirThe serum concentration of Paricalcitol can be increased when it is combined with Telaprevir.Withdrawn
TelithromycinThe serum concentration of Paricalcitol can be increased when it is combined with Telithromycin.Approved
TiclopidineThe metabolism of Paricalcitol can be decreased when combined with Ticlopidine.Approved
TocilizumabThe serum concentration of Paricalcitol can be decreased when it is combined with Tocilizumab.Approved
TrichlormethiazideTrichlormethiazide may increase the hypercalcemic activities of Paricalcitol.Approved, Vet Approved
VenlafaxineThe metabolism of Paricalcitol can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Paricalcitol can be decreased when combined with Verapamil.Approved
VoriconazoleThe serum concentration of Paricalcitol can be increased when it is combined with Voriconazole.Approved, Investigational
ZiprasidoneThe metabolism of Paricalcitol can be decreased when combined with Ziprasidone.Approved
Food InteractionsNot Available
References
Synthesis Reference

Anchel Schwartz, Alexei Ploutno, Koby Wolfman, "Preparation of paricalcitol." U.S. Patent US20070149489, issued June 28, 2007.

US20070149489
General ReferencesNot Available
External Links
ATC CodesH05BX02 — Paricalcitol
AHFS Codes
  • 88:16.00
PDB EntriesNot Available
FDA labelDownload (447 KB)
MSDSNot Available
Clinical Trials
Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentCancer, Breast1
1CompletedTreatmentHealthy Volunteers1
1CompletedTreatmentUnspecified Adult Solid Tumor, Protocol Specific1
1RecruitingTreatmentMalignant Neoplasm of Pancreas1
1TerminatedTreatmentMucinous Adenocarcinoma of the Rectum / Stage IIA Rectal Cancer / Stage IIB Rectal Cancer / Stage IIC Rectal Cancer / Stage IIIB Rectal Cancer / Stage IIIC Rectal Cancer1
1TerminatedTreatmentMultiple Myeloma and Plasma Cell Neoplasm1
2CompletedNot AvailableChronic Kidney Disease (CKD)1
2CompletedDiagnosticHypersensitivity1
2CompletedPreventionCardiovascular Disease (CVD) / End Stage Renal Disease (ESRD) / Hemodialysis-dependent patients / Inflammatory Responses1
2CompletedTreatmentChronic Kidney Disease (CKD)2
2CompletedTreatmentChronic Kidney Disease (CKD) / Diabetic Nephropathies1
2CompletedTreatmentChronic Kidney Disease on Hemodialysis / Hyperparathyroidism, Secondary1
2CompletedTreatmentHyperparathyroidism, Secondary / Transplant, Kidney1
2CompletedTreatmentHemodialysis-dependent patients / Hyperparathyroidism, Secondary2
2CompletedTreatmentHypocalcemia1
2CompletedTreatmentType 2 Diabetes Mellitus1
2RecruitingTreatmentAdenocarcinoma of the Pancreas / Resectable Pancreatic Cancers / Unresectable Pancreatic Cancer1
2RecruitingTreatmentUntreated Metastatic Pancreatic Ductal Adenocarcinoma1
2TerminatedTreatmentMalignant Neoplasm of Prostate / Metastatic Cancers1
2Unknown StatusTreatmentLeukemias / Myelodysplastic Syndromes1
2, 3CompletedTreatmentChronic Kidney Disease (CKD)1
3CompletedTreatmentAlbuminuria / Disorder of Transplanted Kidney / Proteinuria1
3CompletedTreatmentBypass, Gastric / Parathyroid Hormone1
3CompletedTreatmentChronic Kidney Disease (CKD)2
3CompletedTreatmentChronic Kidney Disease (CKD) / Deficiency, Vitamin D / Hyperparathyroidism, Secondary1
3CompletedTreatmentChronic Kidney Disease (CKD) / Left Ventricular Hypertrophy1
3CompletedTreatmentChronic Kidney Disease Stage 3 and 41
3CompletedTreatmentEnd Stage Renal Disease (ESRD)1
3CompletedTreatmentEnd-Stage Renal Disease (ESRD) / Hyperparathyroidism, Secondary1
3CompletedTreatmentHemodialysis-dependent patients / Hyperparathyroidism, Secondary1
3CompletedTreatmentHyperparathyroidism / Hypophosphatemia, Familial1
3CompletedTreatmentKidney Diseases1
3CompletedTreatmentProteinuria1
3CompletedTreatmentRenal Insufficiency,Chronic3
3TerminatedTreatmentChronic Kidney Disease (CKD) Stage 5 / Left Ventricular Hypertrophy1
3TerminatedTreatmentChronic Kidney Disease (CKD) / Coronary Artery Disease / Hyperparathyroidism, Secondary / Hypovitaminosis D1
3WithdrawnTreatmentIgA Nephropathy1
4Active Not RecruitingTreatmentEndstage Renal Disease / Hyperparathyroidism, Secondary1
4CompletedPreventionChronic Kidney Disease (CKD)1
4CompletedPreventionChronic Kidney Disease (CKD) / Coronary Calcification / Deficiency, Vitamin D / Disorders of Calcium and Bone Metabolism1
4CompletedPreventionRenal Failure1
4CompletedTreatmentAnemias / Chronic Kidney Disease (CKD)1
4CompletedTreatmentCardiorenal Syndrome / Chronic Allograft Nephropathy (CAN)1
4CompletedTreatmentCardiovascular Disease (CVD) / Diabetic Nephropathies1
4CompletedTreatmentChronic Kidney Disease (CKD) / Hyperparathyroidism, Secondary3
4CompletedTreatmentChronic Kidney Disease (CKD) / Hemodialysis-dependent patients / Hyperparathyroidism, Secondary1
4CompletedTreatmentChronic Kidney Disease, Stage 5 / Hyperparathyroidism, Secondary1
4CompletedTreatmentDialysis therapy / Hyperparathyroidism, Secondary1
4CompletedTreatmentEnd Stage Renal Disease (ESRD) / Hyperparathyroidism, Secondary1
4CompletedTreatmentHemodialysis-dependent patients / Hypercalcemia / Hyperparathyroidism, Secondary / Parathyroid Hormone / Renal Insufficiency,Chronic1
4CompletedTreatmentHyperparathyroidism, Secondary4
4CompletedTreatmentKidney Failure,Chronic1
4CompletedTreatmentModerate to Severe Secondary Hyperparathyroidism / Stage 5 Chronic Kidney Diseases1
4CompletedTreatmentSecondary Hyperparathyroidism Due to Renal Causes1
4RecruitingTreatmentAnemias1
4TerminatedTreatmentDialysis therapy / Hyperparathyroidism, Secondary1
4TerminatedTreatmentEnd-Stage Kidney Disease1
4TerminatedTreatmentHypercalcemia / Hyperparathyroidism, Secondary / Hyperphosphataemia / Renal Failure1
4TerminatedTreatmentRenal Dysfunction1
Not AvailableActive Not RecruitingTreatmentOf the Pancreas / Previously Untreated Resectable Adenocarcinoma of the Pancreas / Subjects Must Have Previously Untreated Apparently Resectable Adenocarcinoma1
Not AvailableCompletedNot AvailableChronic Kidney Disease (CKD)1
Not AvailableCompletedTreatmentChronic Kidney Disease (CKD)1
Not AvailableCompletedTreatmentChronic Kidney Disease (CKD) / Endothelial Dysfunction / Hypertensive / Inflammatory Reaction1
Not AvailableCompletedTreatmentFabry's Disease / Proteinuria1
Not AvailableCompletedTreatmentHyperparathyroidism, Secondary / Renal Disease, End Stage / Transplant; Failure, Kidney1
Not AvailableCompletedTreatmentHyperparathyroidism / Kidney Diseases1
Not AvailableRecruitingNot AvailableAlport Syndrome / Familial Benign Hematuria / Hereditary Kidney Disease / Pediatric Kidney Disease / Thin Basement Membrane Disease1
Not AvailableTerminatedNot AvailableEnd-Stage Renal Disease (ESRD) / Hyperparathyroidism, Secondary1
Not AvailableTerminatedTreatmentChronic Kidney Disease (CKD) / Deficiency, Vitamin D / Hyperparathyroidism, Secondary1
Not AvailableUnknown StatusDiagnosticChronic Kidney Disease (CKD) / Type 2 Diabetes Mellitus1
Not AvailableWithdrawnTreatmentHeart Failure, Unspecified1
Not AvailableWithdrawnTreatmentProteinuric Renal Disease1
Pharmacoeconomics
Manufacturers
  • Abbott laboratories pharmaceutical products div
  • Abbott laboratories
Packagers
Dosage forms
FormRouteStrength
CapsuleOral1 ug/1
CapsuleOral1 mg/1
CapsuleOral2 ug/1
CapsuleOral2 mg/1
CapsuleOral4 ug/1
CapsuleOral4 mg/1
Capsule, gelatin coatedOral1 ug/1
Capsule, gelatin coatedOral2 ug/1
Capsule, gelatin coatedOral4 ug/1
Capsule, liquid filledOral1 ug/1
Capsule, liquid filledOral2 ug/1
Capsule, liquid filledOral4 ug/1
InjectionIntravenous10 ug/2mL
InjectionIntravenous2 ug/mL
InjectionIntravenous5 ug/mL
Injection, solutionIntravenous2 ug/mL
Injection, solutionIntravenous5 ug/mL
SolutionIntravenous5 mcg
Prices
Unit descriptionCostUnit
Zemplar 4 mcg capsule37.58USD capsule
Zemplar 5 mcg/ml vial28.03USD ml
Zemplar 2 mcg capsule18.79USD capsule
Zemplar 2 mcg/ml vial11.22USD ml
Zemplar 1 mcg capsule9.39USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5246925 No1995-04-172012-04-17Us
US5597815 Yes1996-01-132016-01-13Us
US6136799 Yes1998-10-082018-10-08Us
US6361758 Yes1998-10-082018-10-08Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
logP4.5Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0068 mg/mLALOGPS
logP5.27ALOGPS
logP4.26ChemAxon
logS-4.8ALOGPS
pKa (Strongest Acidic)14.81ChemAxon
pKa (Strongest Basic)-1ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area60.69 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity127.95 m3·mol-1ChemAxon
Polarizability51.11 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9971
Blood Brain Barrier+0.795
Caco-2 permeable+0.776
P-glycoprotein substrateSubstrate0.7667
P-glycoprotein inhibitor INon-inhibitor0.7431
P-glycoprotein inhibitor IINon-inhibitor0.8491
Renal organic cation transporterNon-inhibitor0.8292
CYP450 2C9 substrateNon-substrate0.7968
CYP450 2D6 substrateNon-substrate0.8903
CYP450 3A4 substrateSubstrate0.7662
CYP450 1A2 substrateNon-inhibitor0.8127
CYP450 2C9 inhibitorNon-inhibitor0.8277
CYP450 2D6 inhibitorNon-inhibitor0.948
CYP450 2C19 inhibitorNon-inhibitor0.8491
CYP450 3A4 inhibitorNon-inhibitor0.8409
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6631
Ames testNon AMES toxic0.9116
CarcinogenicityNon-carcinogens0.9111
BiodegradationNot ready biodegradable0.988
Rat acute toxicity4.4277 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9069
hERG inhibition (predictor II)Non-inhibitor0.8015
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as vitamin d and derivatives. These are compounds containing a secosteroid backbone, usually secoergostane or secocholestane.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassSteroids and steroid derivatives
Sub ClassVitamin D and derivatives
Direct ParentVitamin D and derivatives
Alternative ParentsTriterpenoids / Tertiary alcohols / Secondary alcohols / Cyclic alcohols and derivatives / Hydrocarbon derivatives
SubstituentsTriterpenoid / Tertiary alcohol / Cyclic alcohol / Secondary alcohol / Organic oxygen compound / Hydrocarbon derivative / Organooxygen compound / Alcohol / Aliphatic homopolycyclic compound
Molecular FrameworkAliphatic homopolycyclic compounds
External Descriptorsseco-cholestane, hydroxy seco-steroid (CHEBI:7931 ) / Vitamin D2 and derivatives (C08127 ) / C27 bile acids, alcohols, and derivatives (LMST04030163 )

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Zinc ion binding
Specific Function:
Nuclear hormone receptor. Transcription factor that mediates the action of vitamin D3 by controlling the expression of hormone sensitive genes. Recruited to promoters via its interaction with BAZ1B/WSTF which mediates the interaction with acetylated histones, an essential step for VDR-promoter association. Plays a central role in calcium homeostasis.
Gene Name:
VDR
Uniprot ID:
P11473
Uniprot Name:
Vitamin D3 receptor
Molecular Weight:
48288.64 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Andress DL: Vitamin D treatment in chronic kidney disease. Semin Dial. 2005 Jul-Aug;18(4):315-21. [PubMed:16076355 ]
  4. Brancaccio D, Cozzolino M, Pasho S, Fallabrino G, Olivi L, Gallieni M: New acquisitions in therapy of secondary hyperparathyroidism in chronic kidney disease and peritoneal dialysis patients: role of vitamin D receptor activators. Contrib Nephrol. 2009;163:219-26. doi: 10.1159/000223802. Epub 2009 Jun 3. [PubMed:19494617 ]
  5. Wu-Wong JR, Nakane M, Gagne GD, Brooks KA, Noonan WT: Comparison of the pharmacological effects of paricalcitol and doxercalciferol on the factors involved in mineral homeostasis. Int J Endocrinol. 2010;2010:621687. doi: 10.1155/2010/621687. Epub 2010 Mar 2. [PubMed:20204178 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxidoreductase activity
Specific Function:
Has a role in maintaining calcium homeostasis. Catalyzes the NADPH-dependent 24-hydroxylation of calcidiol (25-hydroxyvitamin D(3)) and calcitriol (1-alpha,25-dihydroxyvitamin D(3)). The enzyme can perform up to 6 rounds of hydroxylation of calcitriol leading to calcitroic acid. It also shows 23-hydroxylating activity leading to 1-alpha,25-dihydroxyvitamin D(3)-26,23-lactone as end product.
Gene Name:
CYP24A1
Uniprot ID:
Q07973
Uniprot Name:
1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrial
Molecular Weight:
58874.695 Da
References
  1. Robinson DM, Scott LJ: Paricalcitol: a review of its use in the management of secondary hyperparathyroidism. Drugs. 2005;65(4):559-76. [PubMed:15733015 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Uniprot Name:
Cytochrome P450 3A4
Molecular Weight:
57342.67 Da
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Protein homodimerization activity
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform glucuronidates bilirubin IX-alpha to form both the IX-alpha-C8 and IX-alpha-C12 monoconjugates and diconjugate. Isoform 2 lacks transferase activity but acts as a negative regulator of isoform 1 (By similarity).
Gene Name:
UGT1A4
Uniprot ID:
P22310
Uniprot Name:
UDP-glucuronosyltransferase 1-4
Molecular Weight:
60024.535 Da
Drug created on June 13, 2005 07:24 / Updated on July 23, 2017 14:41